The Structural Genomics Consortium (SCG) at the University of Oxford undertakes research to find the building blocks for the discovery of new drugs.

A collaboration between universities, government bodies and industrial partners led by GlaxoSmithKline (GSK), the SGC has had remarkable success in mapping human proteins. An Open Access policy means that the results of the SGC’s research are freely available to all.

The SCG provides benefits to both academia and industry by ‘scaling up’ research in this area. This allowed GSK to access data on a wider range of proteins then their own research would allow.

In return, GSK supported the expansion and semi-industrialisation of research with their own scientific expertise.

Prof. Chas Bountra of the SGC argues that the project has helped reduce duplication between the efforts of university and business research. Both sides have been able to achieve greater progress than they would have alone.

The SGC is just one example of an area where combining existing efforts from universities and business can be more efficient for both parties and lead to more breakthroughs in research.

Do you have a Success Story to share?

Get in touch at and a member of our team will get back to you.